SF3B10 Inhibitors

Chemical inhibitors of SF3B10 can exert their action through various mechanisms, all converging on the disruption of the splicing process in which this protein is a crucial component. Pladienolide B, Meayamycin, and E7107 directly bind to the SF3B complex, which includes SF3B10, leading to the inhibition of the spliceosome's function - the intricate machinery responsible for accurate mRNA splicing. By interfering with the spliceosome, these molecules prevent the proper removal of introns and the joining of exons, a critical step in producing functional mRNA transcripts. Similarly, Spliceostatin A engages with the SF3B complex and impedes the early stages of spliceosome assembly, which is essential for the later involvement of SF3B10 in the splicing cycle. The actions of these compounds culminate in the disruption of pre-mRNA processing, thereby inhibiting the functional contribution of SF3B10.

Further along this spectrum, Madrasin and Thailanstatin A specifically target the SF3B complex, and by doing so, they compromise the functional integrity of SF3B10 within the splicing cycle. Herboxidiene binds to the SF3B complex, which subsequently leads to the inhibition of the spliceosome's activity, including that of SF3B10. This binding essentially leads to the incorrect splicing of mRNA, which can have profound effects on gene expression. Isoginkgetin disrupts spliceosome assembly, which is a prerequisite for SF3B10's action in mRNA processing. Pladienolide D also targets the SF3B complex, leading to a decline in splicing activity that encompasses the role of SF3B10. Through these various mechanisms, each chemical serves to inhibit the normal functioning of SF3B10, demonstrating a significant impact on the mRNA splicing machinery.